As per the report titled ‘Global COPD Drugs Market- Analysis By Drug Type, Pipeline Drugs, By Region, By Country (2019 Edition) - Forecast to 2023 -- By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India)’, available with Market Study Report, global COPD drugs market is slated to record significant gains, expanding with a CAGR of 2.47% over 2018-2023.
 

Increasing pervasiveness of COPD associated diseases, surging number of patients, and availability of innovative combination drugs are prime factors driving the growth of global COPD drugs market. Rising awareness about COPD, high smoking pervasiveness, escalating pollution levels are further slated to enhance global COPD drugs market. Furthermore, increase in medical expenditures, favorable government policies, increasing collaborations among major companies are also stimulating the industry outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/1673696/
 

Rising geriatric population, technological enhancements in pharmaceutical research companies, and increasing applicability in middle- and low-income countries are anticipated to fuel the market size. However, increasing portfolio of COPD drugs, and patent expiration of some innovative drugs may act as a hindering factor to the market growth during the analysis timeframe.
 

Based on drug type, global COPD drugs market is categorized into anticholinergics, combination therapy, inhaled corticosteroids, beta-agonist, and others. Among these, the report cites that combination segment is project to hold substantial market share in the upcoming years, especially LAMA/ LABA combination and ICS/LAMA/LABA.
 

Speaking of the regional landscape, global COPD drugs market is classified into North America (United States, Canada), Asia-Pacific (India, Japan, China), Europe (Germany, United Kingdom, Italy, France), and Rest of the World. Among these, North America accounts for substantial market share and is predicted to expand continuously over the forecast period, primarily due to vast patient base and increasing focus towards prescribed branded drugs.
 

Major companies operating in global COPD drugs market are Vectura Group Plc, GlaxoSmithKline Plc, C.H. Boehringer Sohn AG & Ko. KG, AstraZeneca Plc, Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., d.b.a., Novartis International AG, Mylan N.V., Cipla Limited, and Sunovion Pharmaceuticals Inc.